New Coronavirus: SARS-COV-2

Abstract

The World Health Organization reported in the early days of 2020 that the world was facing a new coronavirus, a potential pandemic agent. Its etiological agent is the SARS-CoV-2 from the Coronaviridae family, located in the same subfamily as the SARS-CoV, which also appeared in China in November 2002. The agent is an enveloped, positive-stranded RNA virus. It is thought to be of bat origin. While its disease has been initially described as a non-fatal pneumonia, it is now described as Covid-19 disease with a 3.4% mortality rate. The virus, hence the disease, which began in China in late 2019, has spread to 133 countries and autonomous regions, including Turkey in mid-March of 2020. High fever, following dry cough, fatigue, sputum production, respiratory distress, sore throat, headache, muscle and joint pain are the most common symptoms. It can be fatal in the elderly and those with some comorbid diseases. Although various antivirals are tried for its treatment, no approved specific treatment is found yet, and mostly symptomatic agents are used. Vaccine development studies are ongoing. Therefore, today the most effective way of protection is to be careful for the correct personal hygiene and to change of some social behaviors.

Keywords

• SARS-CoV-2

Yeni Koronavirus: SARS-CoV-2

Abstract

Dünya Sağlık Örgütü, 2020 yılının ilk günlerinde, dünyanın potansiyel pandemi ajanı olan yeni bir koronavirüs ile karşı karşıya olduğunu bildirmiştir. Etiyolojik ajanı Coronaviridae ailesinden, 2002 yılı Kasım ayında yine Çin’de ortaya çıkan SARS-CoV ile aynı alt aileye konumlandırılan SARS-CoV-2’dir. Etken zarflı, pozitif polariteli bir RNA virüsüdür. Yarasa kökenli olduğu düşünülmektedir. Yaptığı hastalık başlangıçta ölümcül olmayan bir pnömoni olarak tanımlanırken günümüzde %3.4 ölüm oranına sahip Covid-19 hastalığı olarak nitelendirilmektedir. Virüs, dolayısıyla hastalık, 2019 yılının sonlarında Çin’de başlamış, 2020’nin Mart ayının ortalarında Türkiye dâhil 133 ülke ve özerk bölgeye yayılmıştır. Yüksek ateş, takip eden kuru öksürük, yorgunluk, balgam üretimi, solunum güçlüğü, boğaz, baş, kas ve eklem ağrıları en sık görülen hastalık belirtileridir. Yaşlı ve bazı komorbid hastalığı olanlarda ölümcül seyredebilmektedir. Tedavisinde çeşitli antiviraller denenmesine karşın henüz onaylı tedavi bulunmamaktadır, daha çok semptomatik etkili ajanlar kullanılmaktadır. Aşı geliştirme çalışmaları sürdürülmektedir. Bu nedenle günümüzde en etkili korunma yolu, doğru kişisel hijyen davranışlarını önemseyerek uygulama ve bazı sosyal davranışların ertelenmesidir.

Keywords

• SARS-CoV-2

References

1. 1. WHO Situation Report-54. https://www.who.int/docs/default-source/ coronaviruse/situation-reports/20200314-sitrep-54-covid-19.pdf?sfvrsn=dcd46351_6.
2. 2. Chan JF, To KK, Tse H, Jin DY, Yuen KY. Interspecies transmission and emergence of novel viruses:lessons from bats and birds. Trends Microbiol 2013;21:544-55.
3. 3. Shanmugaraj B, Malla A, Phoolcharoen W. Emergence of Novel Coronavirus 2019-nCoV: Need for rapid vaccine and biologics development. Pathogens 2020 Feb 22[Online ahead of print]
4. 4. Chen Y, Liu Q, Guo D. Emerging coronaviruses:Genome structure, replication, and pathogenesis. J Med Virol 2020;92:418-23.
5. 5. Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Di Napoli R. Features, evaluation and treatment coronavirus (COVID-19). StatPearls Publishing, March 2020.
6. 6. WHO Director-General’s opening remarks at the media briefing on COVID-19 - 3 March 2020 - World Health Organization, March 3, 2020.
7. 7. Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARSCoV- 2. Nat Microbiol 2020 Mar 2 [Online ahead of print]
8. 8. Chan JF, Kok KH, Zhu Z, et al. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg Microbes Infect 2020;9:221-36.

9. 9. Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020;579:270-3.
10. 10. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/namingthe-coronavirus-disease-(covid-2019)-and-the-virus-that-causes-it
11. 11. https://www.medrxiv.org/content/10.1101/2020.03.05.20030502v1
12. 12. Young BE, Ong SWX, Kalimuddin S, et al. Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore. JAMA 2020 Mar 3[Online ahead of print]
13. 13. Chang L, Yan Y, Wang L. Coronavirus Disease 2019: Coronaviruses and blood safety. Transfusion Medicine Reviews 2020 Feb 21[Online ahead of print]
14. 14. To KK-W, Tsang OT-Y, Yip CC-Y, et al. Consistent Detection of 2019 Novel Coronavirus in Saliva. Clin Infect Dis 2020 Feb 12[Online ahead of print]
15. 15. https://www.medrxiv.org/content/10.1101/2020.02.21.20026179v1
16. 16. Cai J, Xu J, Lin D, et al. A Case Series of children with 2019 novel coronavirus infection: clinical and epidemiological features. Clin Infect Dis 2020 Feb 28[Online ahead of print]
17. 17. Backer JA, Klinkenberg D, Wallinga J. Incubation period of 2019 novel coronavirus (2019-nCoV) infections among travellers from Wuhan, China, 20-28 January 2020. Eurosurveillance 2020 Feb [Online ahead of print]
18. 18. https://www.who.int/docs/default-source/coronaviruse/who-china-jointmission-on-covid-19-final-report.pdf.
19. 19. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200306-sitrep-46-covid-19.pdf?sfvrsn=96b04adf_2
20. 20. https://www.ecdc.europa.eu/sites/default/files/documents/RRA-sixth-update-Outbreak-of-novelcoronavirus-disease-2019-COVID-19.pdf